The AAPS Journal

, Volume 8, Issue 3, pp E501–E507 | Cite as

Effects of protein aggregates: An immunologic perspective

  • Amy S. RosenbergEmail author


The capacity of protein aggregates to enhance immune responses to the monomeric form of the protein has been known for over a half-century. Despite the clear connection between protein aggregates and antibody mediated adverse events in treatment with early therapeutic protein products such as intravenous immune globulin (IVIG) and human growth hormone, surprisingly little is known about the nature of the aggregate species responsible for such effects. This review focuses on a framework for understanding how aggregate species potentially interact with the immune system to enhance immune responses, garnered from basic immunologic research. Thus, protein antigens presented in a highly arrayed structure, such as might be found in large nondenatured aggregate species, are highly potent in inducing antibody responses even in the absence of T-cell help. Their potency may relate to the ability of multivalent protein species to extensively cross-link B-cell receptor, which (1) activates B cells via Bt kinases to proliferate, and (2) targets protein to class II major histocompatability complex (MHC)-loading compartments, efficiently eliciting T-cell help for antibody responses. The review further focuses on protein aggregates as they affect an immunogenicity risk assessment, the use of animal models and studies in uncovering effects of protein aggregates, and changes in product manufacture and packaging that may affect generation of protein aggregates.


aggregates container closure system immunogenicity neutralizing antibody tolerance 


  1. 1.
    Dintzis R, Okajima M, Middleton M, Greene G, Dintzis H. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence.J Immunol. 1989;143:1239–1244.PubMedGoogle Scholar
  2. 2.
    Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms.Immunol Rev. 2000;176:154–170.CrossRefPubMedGoogle Scholar
  3. 3.
    Bachmann M, Zinkernagel R. Neutralizing antiviral B-cell responses.Annu Rev Immunol. 1997;15:235–270.CrossRefPubMedGoogle Scholar
  4. 4.
    Fluckiger AC, Li Z, Kato RM, et al. Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation.EMBO J. 1998;17:1973–1985.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ito H-O, Nakashima T, So T, Hirata M, Inoue M. Immunodominance of conformation-dependent B-cell epitopes of protein antigens.Biochem Biophys Res Commun. 2003;308:770–776.CrossRefPubMedGoogle Scholar
  6. 6.
    Nath A, Hall E, Tuzova M, et al. Autoantibodies to Amyloid β-peptide (Aβ) are increased in Alzheimer’s disease patients and Aβ antibodies can enhance Aβ neurotoxicity.Neuromolecular Med. 2003;3:29–39.CrossRefPubMedGoogle Scholar
  7. 7.
    O’Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope.Proc Natl Acad Sci USA. 2002;99:1485–1490.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Casadevall N, Nataf J, Viron B, et al. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin.N Engl J Med. 2002;346:469–475.CrossRefPubMedGoogle Scholar
  9. 9.
    Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin.Blood. 2001;98:3241–3248.CrossRefPubMedGoogle Scholar
  10. 10.
    Chackerian B, Lenz P, Lowy D, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus-like particles.J Immunol. 2002;169:6120–6126.CrossRefPubMedGoogle Scholar
  11. 11.
    Cheng P, Steele C, Gu L, Song W, Pierce S. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens.J Immunol. 1999;162:7171–7180.PubMedGoogle Scholar
  12. 12.
    Frei P, Benacerraf B, Thorbecke GJ. Phagocytosis of the antigen, a crucial step in the induction of the primary response.Proc Natl Acad Sci USA. 1965;53:20–23.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Martin F, Oliver A, Kearney J. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens.Immunity. 2001;14:617–629.CrossRefPubMedGoogle Scholar
  14. 14.
    Weigle WO. Analysis of autoimmunity through experimental models of thyroiditis and allergic encephalomyelitis.Adv Immunol. 1980;30:159–273.CrossRefPubMedGoogle Scholar
  15. 15.
    Goodnow CC. Transgenic mice and analysis of B-cell tolerance.Annu Rev Immunol. 1992;10:489–518.CrossRefPubMedGoogle Scholar
  16. 16.
    Kyewski B, Derbinski J. Self-representation in the thymus: an extended view.Nat Rev Immunol. 2004;4:688–698.CrossRefPubMedGoogle Scholar
  17. 17.
    Aalberse R, Platts-Mills T. How do we avoid developing allergy: modifications of the Th2 response from a B-cell perspective.J Allergy Clin Immunol. 2004;113:983–986.CrossRefPubMedGoogle Scholar
  18. 18.
    Spiegelberg H, Horner A, Takabayashi K, Raz E. Allergen immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy.Curr Opin Allergy Clin Immunol. 2002;2:547–551.CrossRefPubMedGoogle Scholar
  19. 19.
    Cleland J, Powell M, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.Crit Rev Ther Drug Carrier Syst. 1993;10:307–377.PubMedGoogle Scholar
  20. 20.
    Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals.Int J Pharm. 1999;185:129–188.CrossRefPubMedGoogle Scholar
  21. 21.
    Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulationsJ Pharm Sci. 2004;93:1390–1402.CrossRefPubMedGoogle Scholar
  22. 22.
    Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity?Pharm Res. 2003;20:1903–1907.CrossRefPubMedGoogle Scholar
  23. 23.
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn’s disease.N Engl J Med. 2003;348:601–608.CrossRefPubMedGoogle Scholar
  24. 24.
    Ring J, Stephan W, Brendel W. Anaphylactoid reactions to infusions of plasma protein and human serum albumin.Clin Allergy. 1979;9:89–97.CrossRefPubMedGoogle Scholar
  25. 25.
    Dresser DW. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen.Immunology. 1962;5:378–388.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Gamble CN. The role of soluble aggregates in the primary immune response of mice to human gamma globulin.Int Arch Allergy Appl Immunol. 1966;30:446–455.CrossRefPubMedGoogle Scholar
  27. 27.
    Getahun A, Heyman B. How antibodies act as natural adjuvants.Immunol Lett. 2006;104:38–45.CrossRefPubMedGoogle Scholar
  28. 28.
    Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice.Pharm Res. 1997;14:1472–1478.CrossRefPubMedGoogle Scholar
  29. 29.
    Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human γ-globulin.Vox Sang. 1962;7:157–174.CrossRefPubMedGoogle Scholar
  30. 30.
    Ellis E, Henney C. Adverse reactions following administration of human gamma globulin.J Allergy. 1969;43:45–54.CrossRefPubMedGoogle Scholar
  31. 31.
    Moore W, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH.J Clin Endocrinol Metab. 1980;51:691–697.CrossRefPubMedGoogle Scholar
  32. 32.
    Staff PDR, ed. Proleukin. In:2004 Physicians Desk Reference. 58th ed. Montvale, NJ: Thomson Health care; 2004;1163–1167.Google Scholar
  33. 33.
    Prummer O. Treatment-induced antibodies to interleukin 2.Biotherapy. 1997;10:15–24.CrossRefPubMedGoogle Scholar
  34. 34.
    Ishiguro A, Nakahata T, Matsubara K, et al. Age-related changes in thrombopoietin in children: reference interval for serum thrombopoietin levels.Br J Haematol. 1999;106:884–888.CrossRefPubMedGoogle Scholar
  35. 35.
    Novotny J, Handschumacher M, Haber E, et al. Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains).Proc Natl Acad Sci USA. 1986;83:226–230.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Li P, Azizul H, Blum J. Role of disulfide bonds in regulating antigen processing and epitope selection.J Immunol. 2002;169:2444–2450.CrossRefPubMedGoogle Scholar
  37. 37.
    Alliance Protein Laboratories Web site. Summary of characterization methods offered. Available at: Accessed July 6, 2006.Google Scholar
  38. 38.
    Liu J, Shire SJ. Analytical ultracentrifugation in the pharmaceutical industry.J Pharm Sci. 1999;88:1237–1241.CrossRefPubMedGoogle Scholar
  39. 39.
    Wyatt Technology corporation Web site. Theory. Available at: Accessed July 6, 2006.Google Scholar
  40. 40.
    Koppaka V, Murray P, Axelsen P. Early synergy between Abeta 42 and oxidatively damaged membranes in promoting amyloid fibril formation by Abeta40.J Biol Chem. 2003;278:36277–36284.CrossRefPubMedGoogle Scholar
  41. 41.
    Levin S. Field flow fractionation in biomedical analysis.Biomed Chromatogr. 1991;5:133–137.CrossRefPubMedGoogle Scholar
  42. 42.
    Fraunhofer W, Winter G, Coester C. Asymmetrical flow field-flow fractionation and multiangle light scattering for analysis of gelatin nanoparticle drug carrier systems.Anal Chem. 2004;76:1909–1920.CrossRefPubMedGoogle Scholar
  43. 43.
    Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.Kidney Int. 2005;67:2346–2353.CrossRefPubMedGoogle Scholar
  44. 44.
    Peerlinck K, Arnout J, Di Giambattista M, et al. Factor VIII inhibitors in previously treated hemophilia A patients with a double virus inactivated plasma derived factor VIII concentrate.Thromb Haemost. 1997;77:80–86.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2006

Authors and Affiliations

  1. 1.Division of Therapeutic Proteins, Food and Drug AdministrationCenter for Drug Evaluation and ResearchBethesda

Personalised recommendations